Avicanna

Avicanna EBITDA per Share

The EBITDA per Share of Avicanna (AVCN.TO) as of Nov 21, 2026 is -0.02 CAD. In the previous year, EBITDA per Share was -0.03 CAD — a change of -34.05% (higher).

EBITDA per Share

-0.02CAD

YoY

-34.05%

Last updated:

EBITDA per Share of Avicanna is 2025 -0.02 CAD. EBITDA per Share of Avicanna was 2024 -0.03 CAD. It decreases by -34.05% higher compared to the previous year.

The Avicanna EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.56 CAD
Jan 1, 2019
-0.84 CAD
Jan 1, 2020
-0.81 CAD
Jan 1, 2021
-0.37 CAD
Jan 1, 2022
-0.16 CAD
Jan 1, 2023
-0.08 CAD
Jan 1, 2024
-0.03 CAD
Jan 1, 2025
-0.02 CAD
The Avicanna EBITDA per Share history
YEAREBITDA per ShareYoY
-0.02CAD-34.05%
-0.03CAD-55.20%
-0.08CAD-52.28%
-0.16CAD-55.69%
-0.37CAD-54.81%
-0.81CAD-3.38%
-0.84CAD+50.42%
-0.56CAD+267.34%
-0.15CAD+64,195.30%
-0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Avicanna Stock analysis

What does Avicanna do? Avicanna Inc is a Canadian biopharmaceutical company specializing in the research, development, and manufacturing of medical marijuana products. The company was founded in 2016 by its president and CEO Aras Azadian, who has extensive experience in the pharmaceutical and biotechnology industry. The company is based in Toronto, Canada and also operates in Colombia and Switzerland. Avicanna has several subsidiaries, including Santa Marta Golden Hemp, which operates its cultivation business in Colombia. Avicanna's business model is focused on producing medical marijuana products that have better efficacy and tolerability than conventional products. The company uses a specialized process called PhytoVista™ to isolate and extract the active ingredients in plant extracts. Avicanna operates in various sectors, including the manufacturing and marketing of medical marijuana products, research and development of effective medical treatments, and collaboration with healthcare facilities and government agencies in marijuana regulation. The company offers a variety of products, including different types of hemp oil, CBD products, and pharmaceutical products such as Rho PhytoTM and Pura EarthTM. These products all share the common approach of providing patients with better, more effective, and tolerable treatment options. Rho PhytoTM is a patented medical marijuana product by Avicanna, derived from a specific cannabis strain called ACMPR. This product is approved in Canada and available as an oral solution and syringe. Rho PhytoTM is specifically tailored to meet the needs of patients with neurodegenerative diseases and has proven to be effective. Pura EarthTM is a herbal remedy derived from the medical marijuana plant and is intended to be used as an alternative medicine for pain and inflammation. In addition to manufacturing medical marijuana products, the company also conducts intensive research and development to develop medications based on synthetic cannabinoids. These substances have the potential to help patients with various conditions such as multiple sclerosis, epilepsy, and tumor diseases. Avicanna also has partnerships with various healthcare facilities and government agencies to advance the regulation of medical marijuana and ensure the safety and efficacy of these products. In summary, Avicanna is an innovative biopharmaceutical company specializing in the manufacturing and marketing of medical marijuana products. The company serves various areas within the marijuana industry, including the production of medical products, research and development, and regulation of marijuana products. With an extensive product range and a strong research and development department, Avicanna is well positioned to continue growing and developing more innovative products in the coming years. Avicanna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Avicanna stock

EBITDA per Share of Avicanna is -0.02 CAD in 2025.

EBITDA per Share of Avicanna changed from -0.03 CAD to -0.02 CAD, representing a -34.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Avicanna since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Avicanna

All Key Metrics — Avicanna